Breaking News Instant updates and real-time market news.

TEVA

Teva

$32.11

-0.0052 (-0.02%)

14:34
04/13/17
04/13
14:34
04/13/17
14:34

Teva receives FDA warning over China facility, says taking corrective actions

Teva disclosed in a regulatory filing: "On April 10, Teva received a Warning Letter from the U.S. Food and Drug Administration. The Warning Letter is connected with a routine FDA current Good Manufacturing Practices inspection of the company's API manufacturing facility in China, which was conducted September 26-29, 2016. The letter cites concerns with manufacturing control and sampling processes. Teva is already in the process of undertaking corrective actions to address both the specific concerns raised by investigators as well as the underlying causes of those concerns. Communication with the FDA is ongoing. Teva will respond to the Warning Letter by May 1."

  • 04

    May

  • 11

    May

  • 30

    Aug

TEVA Teva
$32.11

-0.0052 (-0.02%)

03/07/17
JEFF
03/07/17
NO CHANGE
Target $33
JEFF
Buy
Supernus settlement modestly better than expected, says Jefferies
Jefferies analyst David Steinberg says Supernus Pharmaceuticals (SUPN) should be able maintain exclusivity on 65% of Trokendi XR sales until January 2023 following its settlement with Zydus Pharmaceutical. The analyst views the settlement as modestly better than his forecast. Should Supernus secure a similar settlement with Teva (TEVA), it would be well positioned to transition the revenue stream from its current epilepsy franchises to two late-stage pipeline candidates, Steinberg tells investors in a research note. He keeps a Buy rating on Supernus with a $33 price target.
04/06/17
OPCO
04/06/17
NO CHANGE
Target $43
OPCO
Outperform
Teva Austedo approval 'a nice incremental positive,' says Oppenheimer
Oppenheimer analyst Derek Archila notes that Teva (TEVA) received approval for Austedo for Huntington's chorea, which he sees as "a nice positive" given the company's recent challenges. Based on his review of the label and recent physician checks, the analyst believes Austedo could potentially become first-line therapy for Huntington's chorea and forecasts sales of about $600M by 2022 in this indication. Archila continues to like Teva's shares long term, though he expects they may be range-bound until a new CEO is hired, generic business stabilizes, and Allergan's (AGN) stake in Teva is resolved. He reiterates an Outperform rating and $43 price target on Teva's shares.
04/12/17
JEFF
04/12/17
NO CHANGE
Target $43
JEFF
Buy
Jefferies views Alder concerns as overblown, sees buying opportunity
After spending time with an intellectual property expert, Jefferies analyst Brian Abrahams believes IP concerns relating to Alder Biopharmaceuticals (ALDR) remain overdone. He does not believe Teva's (TEVA) patents will be upheld as valid in the U.S. Abrahams does not think IP conflicts would dissuade potential partners and/or acquirers and keeps a Buy rating on Alder with a $43 price target. The analyst sees a buying opportunity at current levels into the Phase III data.
04/12/17
LEER
04/12/17
NO CHANGE
Target $68
LEER
Outperform
Neurocrine Valbenazine approved with 'best case,' says Leerink
Following Neurocrine's (NBIX) announcement of FDA approval of Ingrezza, or valbenazine, for adults with Tardive Dyskinesia, Leerink analyst Paul Matteis says that the language in the label looks to be a best-case scenario for the company as it outlines few safety risks and does not contain a black box warning for increased risk of suicidality. The analyst believes the latter adds to valbenazine's advantages over Teva's (TEVA) SD-809. Matteis moved his odds of FDA approval from 90% to 100%, reiterated an Outperform rating on Neurocrine's stock and raised his price target on the shares to $68 from $65.

TODAY'S FREE FLY STORIES

QADA

QAD Inc.

$39.95

1.75 (4.58%)

07:51
11/22/17
11/22
07:51
11/22/17
07:51
Recommendations
QAD Inc. analyst commentary  »

QAD Inc. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$8.25

-2.85 (-25.68%)

07:48
11/22/17
11/22
07:48
11/22/17
07:48
Downgrade
Cytokinetics rating change  »

Cytokinetics downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.43 (1.33%)

07:46
11/22/17
11/22
07:46
11/22/17
07:46
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

07:45
11/22/17
11/22
07:45
11/22/17
07:45
General news
U.S. MBA mortgage market index rose 0.1% »

U.S. MBA mortgage market…

CYTK

Cytokinetics

$8.25

-2.85 (-25.68%)

07:43
11/22/17
11/22
07:43
11/22/17
07:43
Recommendations
Cytokinetics analyst commentary  »

Cytokinetics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$139.23

2.31 (1.69%)

07:43
11/22/17
11/22
07:43
11/22/17
07:43
Technical Analysis
Technical View: Deere at new 52-week high after results beat expectations »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 28

    Nov

CRM

Salesforce

$108.80

1.43 (1.33%)

07:42
11/22/17
11/22
07:42
11/22/17
07:42
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

07:40
11/22/17
11/22
07:40
11/22/17
07:40
General news
Treasury Market Outlook: longer dated bond yields are modestly higher »

Treasury Market Outlook:…

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

07:39
11/22/17
11/22
07:39
11/22/17
07:39
Technical Analysis
Technical View: Axalta Coating up on Nippon Paint takeover talks »

The company earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.44 (1.34%)

07:39
11/22/17
11/22
07:39
11/22/17
07:39
Recommendations
Salesforce analyst commentary  »

Canaccord has 'no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

OSUR

OraSure

$16.55

2.59 (18.55%)

07:36
11/22/17
11/22
07:36
11/22/17
07:36
Recommendations
OraSure analyst commentary  »

OraSure contract win…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$16.73

0.29 (1.76%)

07:35
11/22/17
11/22
07:35
11/22/17
07:35
Technical Analysis
Technical View: GameStop trades higher after earnings and outlook »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$14.67

0.15 (1.03%)

07:35
11/22/17
11/22
07:35
11/22/17
07:35
Recommendations
Nuance analyst commentary  »

In-line guidance likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

AAPL

Apple

$173.14

3.16 (1.86%)

, BAC

Bank of America

$26.73

-0.01 (-0.04%)

07:35
11/22/17
11/22
07:35
11/22/17
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

AAPL

Apple

$173.14

3.16 (1.86%)

BAC

Bank of America

$26.73

-0.01 (-0.04%)

MU

Micron

$49.40

1.76 (3.69%)

T

AT&T

$34.33

-0.31 (-0.89%)

ORCL

Oracle

$48.63

-0.39 (-0.80%)

AKS

AK Steel

$4.85

0.22 (4.75%)

PG

Procter & Gamble

$88.72

0.45 (0.51%)

TRIP

TripAdvisor

$32.81

2.33 (7.64%)

PEP

PepsiCo

$116.05

1.14 (0.99%)

PAGP

Plains GP Holdings

$20.48

-0.41 (-1.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 29

    Nov

  • 19

    Dec

EKSO

Ekso Bionics

$4.13

1.21 (41.44%)

07:33
11/22/17
11/22
07:33
11/22/17
07:33
Technical Analysis
Technical View: Ekso Bionics trades sharply higher, edging 52-week high »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$30.20

0.5 (1.68%)

07:32
11/22/17
11/22
07:32
11/22/17
07:32
Initiation
Nutanix initiated  »

Nutanix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 07

    Dec

  • 12

    Dec

HPE

HP Enterprise

$14.12

0.03 (0.21%)

07:32
11/22/17
11/22
07:32
11/22/17
07:32
Recommendations
HP Enterprise analyst commentary  »

HP Enterprise CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 11

    Dec

GE

General Electric

$17.83

-0.15 (-0.83%)

, DKS

Dick's Sporting

$28.58

-0.52 (-1.79%)

07:30
11/22/17
11/22
07:30
11/22/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

GE

General Electric

$17.83

-0.15 (-0.83%)

DKS

Dick's Sporting

$28.58

-0.52 (-1.79%)

ROST

Ross Stores

$72.67

-0.07 (-0.10%)

ILG

ILG

$28.11

-0.5 (-1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 30

    Nov

  • 01

    Dec

  • 12

    Dec

DLTR

Dollar Tree

$99.46

2.35 (2.42%)

07:29
11/22/17
11/22
07:29
11/22/17
07:29
Recommendations
Dollar Tree analyst commentary  »

Dollar Tree price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:28
11/22/17
11/22
07:28
11/22/17
07:28
General news
Futures above fair value ahead of holiday »

Stock futures are…

SHOO

Steven Madden

$39.80

-0.6 (-1.49%)

07:28
11/22/17
11/22
07:28
11/22/17
07:28
Conference/Events
Steven Madden management to meet with Buckingham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

BURL

Burlington Stores

$104.94

-1.61 (-1.51%)

07:25
11/22/17
11/22
07:25
11/22/17
07:25
Recommendations
Burlington Stores analyst commentary  »

Burlington Stores price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLH

Red Lion Hotels

$8.55

0.1 (1.18%)

07:24
11/22/17
11/22
07:24
11/22/17
07:24
Conference/Events
Red Lion Hotels management to meet with Craig Hallum »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 30

    Nov

  • 06

    Dec

TIVO

TiVo

$17.65

0.15 (0.86%)

, CMCSA

Comcast

$36.42

0.59 (1.65%)

07:24
11/22/17
11/22
07:24
11/22/17
07:24
Recommendations
TiVo, Comcast, Comcast analyst commentary  »

TiVo ITC win raises odds…

TIVO

TiVo

$17.65

0.15 (0.86%)

CMCSA

Comcast

$36.42

0.59 (1.65%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$184.15

1.81 (0.99%)

07:22
11/22/17
11/22
07:22
11/22/17
07:22
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.